smashed on a positive outcome of research into the effect of Ozempic on kidney disease...
You seem to be the only one who has a handle on what is going on here. Looks like every time a positive outcome from research into Ozempic RMD is going to get smashed.
I think in only your second post ever when RMD was $25, you mentioned a trial on the effect of GLP-1s on sleep apnea with results coming out in March '24.
Now that will be an absolute doozy when those results hit markets because that study focuses not on weight lose or kidney function but what RMD is all about - sleep apnea. In fact I would say the fate of the company will be largely determined by that one piece of info on that very day.
We will then know if RMD is 20 something PE stock or a 15 PE stock, forget about 30x earnings. those days are gone.
Ann: ResMed Announces Results for the Fourth Quarter of FY2023, page-350
Add RMD (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$37.39 |
Change
0.390(1.05%) |
Mkt cap ! $22.84B | |||
| Open | High | Low | Value | Volume |
| $37.30 | $37.39 | $37.07 | $9.729M | 260.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 44 | $37.32 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $37.39 | 2573 | 2 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| RMD (ASX) Chart |